How to find a new drug that can cure cancer
In a world where doctors and scientists are fighting over the use of powerful anti-cancer drugs, a new cancer treatment that might work on a few dozen people has caught the attention of the pharmaceutical industry.
In a way, it’s an unexpected turn of events.
Since the 1960s, there have been several drugs that have been shown to be effective in reducing the growth of cancer cells.
In many cases, these drugs are not just a powerful treatment but also help doctors to keep their patients alive and prevent the spread of the cancer.
In fact, the drugs can help cancer patients live longer, but they have also been shown not to cure the cancer or even prevent the development of the disease.
Now, researchers at the University of Michigan say they have found a new type of cancer drug that could help to combat a number of different types of cancer.
“We have the ability to treat cancer cells with a drug that is not only more potent, but also less toxic than the standard cancer drug,” said Dr. David P. Shulman, a professor of biochemistry and molecular biology at the university.
Dr. Shushman and his colleagues tested the drug they developed to treat breast cancer with a compound called SARM.
The compound is a protein that has a large number of cytoplasmic regions that are known to be cancerous.
The team tested the compound against the proteins in human breast cancer cells to see if it could knock out the cancer cells without harming normal cells.
They found that the compound blocked the growth and activity of the cells and also blocked the cancerous cytoplonemal cells.
This meant the drugs helped the cancer patients to live longer.
“If you want to treat a lot of people, you want a drug to kill the cells, and the drug we’ve found is a way to do that,” Dr. Shurman said.
The scientists are now working to develop a drug specifically designed to treat the disease, but for now, the scientists are focusing on the potential of this new compound to treat leukemia.
“Our hope is that we can figure out a way that can treat this kind of leukemia in a way without killing normal cells,” Dr Shushmann said.
It is not yet known how the drug works, but Dr Shulmans team believes it is the result of some sort of interaction between two proteins that have a common function in cells.
“The protein that controls the cell division is known as the cell cycle control factor,” Dr Schulman said, “and this is a very important molecule in the cell that we have to get rid of.”
Dr. Schulmans group hopes to develop the drug in the next five to 10 years and then commercialize it.
He said the next step will be testing whether the compound can be used in humans as a treatment.
“It’s very early in the development process and we’ve been looking for about two years,” Dr Siegel said.
Dr Shulmen hopes that the drug will be effective for about 1,000 patients a year.